AbbVie
Trade AbbVie 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About ABBV
AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders such as Parkinson’s disease, metabolic disorders, including thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions.
ABBV Key Statistics
Stock Snapshot
The current AbbVie(ABBV) stock price is $263.25, with a market capitalization of 469.67B. The stock trades at a price-to-earnings (P/E) ratio of 74.31 and offers a dividend yield of 2.60%.
On 2026-10-05, AbbVie(ABBV) stock traded between a low of $260.29 and a high of $267.34. Shares are currently priced at $263.25, which is +1.1% above the low and -1.5% below the high.
AbbVie(ABBV) shares are trading with a volume of 7.54M, against a daily average of 3.83M.
During the past year, AbbVie(ABBV) stock moved between $190.75 at its lowest and $269.39 at its peak.
During the past year, AbbVie(ABBV) stock moved between $190.75 at its lowest and $269.39 at its peak.
ABBV News
AbbVie (ABBV Quick QuoteABBV - Free Report) closed the most recent trading day at $265.85, moving +1.15% from the previous trading session. The stock outp...
The company states: “Reported GAAP earnings and adjusted non-GAAP earnings for the third quarter of 2026 are expected to include acquired IPR&D and milestones e...
...
Analyst ratings
75%
of 32 ratingsMore ABBV News
An announcement from Genmab ( (GMAB) ) is now available. Genmab and AbbVie reported on October 5, 2026, that their Phase 3 EPCORE DLBCL-2 trial showed epcorita...
Genmab A/S (GMAB) and AbbVie (ABBV) announced “positive” topline results from the Phase 3 EPCORE DLBCL-2 trial evaluating fixed treatment duration epcoritamab,...
AbbVie (ABBV) just packed several pipeline updates into a short window, from FDA clearance of Parkinson's therapy JUVMO to fresh RINVOQ vitiligo data and new on...
Earlier this week, the U.S. Food and Drug Administration (FDA) approved AbbVie's (ABBV +1.11%) Juvmo (tavapadon). This is a once-daily pill for adults with Park...
Abbvie (ABBV) announced an update on their ongoing clinical study. AbbVie’s latest study, NCT05317494, tracks how its leukemia drug Venetoclax works in everyda...
Healthcare investors often face a dilemma when choosing between established giants, but AbbVie (ABBV -0.64%) and Bristol Myers Squibb (BMY -1.51%) present two v...
AbbVie (ABBV) announced late-breaking results from the ongoing Phase 3 Viti-Up-1 and Viti-Up-2 studies of RINVOQ in non-segmental vitiligo, showing continued fa...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.